These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 8054913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H.
    Blood; 1998 Dec 15; 92(12):4581-90. PubMed ID: 9845524
    [Abstract] [Full Text] [Related]

  • 6. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z.
    Br J Haematol; 1995 Mar 15; 89(3):506-15. PubMed ID: 7734348
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May 15; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW, Craston R, Ray N, Koh M, Galatowicz G, Prentice HG.
    Bone Marrow Transplant; 1998 Apr 15; 21(7):679-86. PubMed ID: 9578307
    [Abstract] [Full Text] [Related]

  • 12. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 13. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D.
    BioDrugs; 2003 Mar 15; 17(3):147-54. PubMed ID: 12749751
    [Abstract] [Full Text] [Related]

  • 14. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H, CAMPATH Users.
    Cytotherapy; 2001 Mar 15; 3(3):145-64. PubMed ID: 12171722
    [Abstract] [Full Text] [Related]

  • 15. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
    Willemze R, Richel DJ, Falkenburg JH, Hale G, Waldmann H, Zwaan FE, Fibbe WE.
    Bone Marrow Transplant; 1992 Apr 15; 9(4):255-61. PubMed ID: 1600413
    [Abstract] [Full Text] [Related]

  • 16. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N, Thomas V, du Toit C.
    Cytotherapy; 2008 Apr 15; 10(1):45-53. PubMed ID: 18202974
    [Abstract] [Full Text] [Related]

  • 17. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ, Kapoor N, Crooks GM, Weinberg KI, Azim HA, Killen R, Kuo L, Rushing T, Kohn DB, Parkman R.
    Biol Blood Marrow Transplant; 2007 May 15; 13(5):584-93. PubMed ID: 17448918
    [Abstract] [Full Text] [Related]

  • 18. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E, Delukina M, Or R, Nagler A, Kapelushnik J, Varadi G, Strauss N, Cividalli G, Aker M, Brautbar C, Waldmann H, Hale G, Slavin S.
    Exp Hematol; 1999 Jul 15; 27(7):1210-8. PubMed ID: 10390197
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A.
    Pediatrics; 1996 Sep 15; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [Abstract] [Full Text] [Related]

  • 20. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, Ortin M, Freires M, Hale G, Waldmann H, Gordon-Smith EC, Marsh JC.
    Biol Blood Marrow Transplant; 2004 Dec 15; 10(12):867-76. PubMed ID: 15570255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.